The Indian wellness landscape is undergoing a significant regulatory transformation.On April 16, 2026, the Food Safety and Standards Authority of India (FSSAI) issued a critical advisory explicitly prohibiting the use of Ashwagandha leaves—in crude, extract,or any other form within food and nutraceutical products.
This move, supported by the Ministry of AYUSH,clarifies a long-standing debate in the herbal industry.While Ashwagandha (Withania somnifera) remains a crown jewel of Indian traditional medicine,the regulator has now drawn a firm line:only roots and root extracts are permitted for human consumption in health supplements.
What Exactly Has Changed?
The FSSAI has clarified that under Schedule IV of the 2016 Nutraceutical Regulations,the “approved” part of the Ashwagandha plant is strictly its root.
The New Compliance Standards
* Permitted: Ashwagandha roots and root extracts.
- Prohibited: Ashwagandha leaves, leaf extracts, and any formulation combining the two.
- Scope: This applies to health supplements, functional foods, nutraceuticals, and “Food for Special Dietary Use” (FSDU).
- Enforcement: State food safety commissioners have been directed to initiate legal action against violators under the Food Safety and Standards Act, 2006.
Why the Focus on Leaves? The Science of Safety
The primary reason for this restriction is consumer safety,driven by biochemical differences between the plant’s parts.
1. High Concentration of Withaferin-A
Scientific evidence indicates that Ashwagandha leaves contain significantly higher levels of Withaferin-A compared to roots.While Withaferin-A is studied for its cytotoxic (cell-killing) properties in cancer research,it can be harmful in daily wellness supplements.
2. Potential Health Risks
The FSSAI and Ministry of AYUSH flagged several concerns regarding leaf-based extracts, including:
- Liver Toxicity: Reports have linked unstandardized leaf consumption to hepatotoxicity.
- Gastrointestinal Distress: Potential for severe stomach irritation.
- Neurotoxic Effects: Concerns over how leaf-based compounds interact with the nervous system at high doses.
3. Lack of Traditional Validation
Traditional Ayurvedic texts have overwhelmingly endorsed the use of roots for internal consumption for over 3,000 years.Modern clinical trials reflect this;approximately 73 out of 74 major clinical studies on Ashwagandha utilize root-based formulations, confirming their safety and efficacy for stress and sleep.
Impact on the $38 Billion Nutraceutical Industry
This regulatory “shock” is expected to reshape the $38.77 billion Indian nutraceutical market,which is projected to grow to $84.99 billion by 2033.
Immediate Business Challenges
- Reformulation Costs: Brands that used leaf extracts—often chosen because they are cheaper than roots—must now reformulate their products.
- Supply Chain Shift: The price of raw materials will likely rise. Ashwagandha leaves cost roughly ₹3/kg, whereas high-quality roots can cost between ₹250–₹300/kg.
- Inventory Write-offs: Companies holding large stocks of leaf-based products face significant financial losses and the need for re-labeling.
Who is Affected?
Major industry players like Himalaya Wellness,Patanjali, Dabur,and Baidyanath will need to ensure 100% root-only compliance to avoid penalties of up to ₹10 lakh.
What This Means for You: The Consumer Perspective
For the average consumer, this move is a “win” for transparency and long-term health.
- Safer Supplements: You can now be more confident that approved Ashwagandha products in India are based on the safer,root-extract standard.
- Label Vigilance: Always check the back of the pack. A compliant label should specify that it uses “Ashwagandha Root Extract” rather than generic “Ashwagandha Extract” or “Leaf Powder”.
- Quality over Price: Cheaper supplements often use leaves to cut costs. The FSSAI mandate ensures that brands cannot compromise safety for a lower price point.
Summary of the FSSAI Directive
The Path Forward: Building Global Trust
The restriction on Ashwagandha leaves is part of a larger effort to bring discipline to India’s herbal sector.By aligning with international safety standards and traditional wisdom, India aims to strengthen its position as a global leader in wellness.
As the FSSAI increases vigilance, consumers can expect a market where “natural” truly means “safe.” For brands, the message is clear: Invest in research, stick to the roots, and prioritize consumer safety above all.